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Brief Communications
Haploinsufficiency of Human APOE Reduces Amyloid
Deposition in a Mouse Model of Amyloid- Amyloidosis
Jungsu Kim, Hong Jiang, Seonha Park, Adam E. M. Eltorai, Floy R. Stewart, Hyejin Yoon, JacobM. Basak,
Mary Beth Finn, and David M. Holtzman
Department of Neurology, Developmental Biology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington
University School of Medicine, St. Louis, Missouri 63110
The 4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for Alzheimer’s disease (AD). Evidence suggests that
the effect of apoE isoforms on amyloid- (A) accumulation in the brain plays a critical role in AD pathogenesis. Like in humans, apoE4
expression in animal models that develop A amyloidosis results in greater A and amyloid deposition than with apoE3 expression.
However,whetherdecreasing levels of apoE3orapoE4wouldpromoteor attenuateA-relatedpathologyhasnotbeendirectly addressed.
To determine the effect of decreasing human apoE levels on A accumulation in vivo, we generated human APOE isoform haploinsuffi-
cient mousemodels by crossingAPPPS1-21mice withAPOE isoform knock-inmice. By genetically manipulatingAPOE gene dosage, we
demonstrate that decreasing human apoE levels, regardless of isoform status, results in significantly decreased amyloid plaque deposi-
tion and microglial activation. These differences in amyloid load between apoE3- and apoE4-expressing mice were not due to apoE4
protein being present at lower levels than apoE3. These data suggest that current therapeutic strategies to increase apoE levels without
altering its lipidation state may actually worsen A amyloidosis, while increasing apoE degradation or inhibiting its synthesis may be a
more effective treatment approach.
Introduction
Aggregation and accumulation of amyloid  (A) in the brain is
a key initiating factor in the pathogenesis of Alzheimer’s disease
(AD) (Holtzman et al., 2011). Familial AD-causing mutations in
amyloid  precursor protein (APP), presenilin 1 (PS1), and PS2
genes have provided strong support for the crucial role of A
aggregation in AD pathogenesis (Holtzman et al., 2011). The
strongest genetic risk factor for the most common form of late-
onset AD is the 4 allele of the apolipoprotein E (APOE) gene
(Strittmatter et al., 1993). Although several mechanisms for the
effect of apoE4 on AD pathogenesis have been proposed, the
primary pathway appears to be the differential effects of apoE3
and apoE4 isoforms on A aggregation and clearance (Kim et al.,
2009a; Castellano et al., 2011).
In addition to isoform status, it appears that the amount of
apoE also plays a role in determining the extent of A accumula-
tion in the brain. There has been intense debate as to whether
potential AD therapeutics should increase or decrease apoE levels
(Ashford, 2002; Rebeck et al., 2002; Teter et al., 2002;Osherovich,
2009). Initial studies clearly indicated that the deletion of the
endogenous murine APOE gene causes a dramatic decrease in
fibrillar and total A deposition inAPP transgenicmousemodels
(Bales et al., 1997). However, whether decreasing human apoE
levels will have the same beneficial effect or not has not yet been
answered. Some recent studies indirectly suggest that increasing,
rather than decreasing, human apoE levels may be a good thera-
peutic approach. Therefore, understanding how modulation of
human apoE levels will alter AD pathology must be addressed
before the development of apoE-targeting drugs.
To directly test the effect of human APOE gene dosage on
amyloid pathology, we generated A-depositing mouse mod-
els homozygous or hemizygous for the APOE3 or APOE4 gene.
APPPS1–21 mice with two copies of APOE (APOE3/3 or
APOE4/4 ) or one copy of APOE (APOE3/ or APOE4/)
were generated by breeding APPPS1-21 mice with human
APOE knock-in mice. Compared with the respective homozy-
gous mice, APOE3/ and APOE4/ hemizygous mice had
significantly decreased A accumulation, amyloid deposition,
and microgliosis. Our results strongly suggest that the reduc-
tion of human apoE levels, regardless of the isoform present,
will decrease A-related AD pathology.
Materials andMethods
Generation of human APOE isoform mice with APPswe/PS1(L166P) mu-
tant transgenes. To determine the gene dosage effect of human APOE3
and APOE4 on amyloid deposition, we used knock-in mouse models in
which the endogenous murine Apoe gene is replaced with the APOE3 or
APOE4 gene. Breeding pairs were gifts from Dr. Patrick Sullivan, Duke
University, Durham, NC (Sullivan et al., 1997). APPPS1-21 mice over-
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express a humanAPPwith a Swedishmutation
(KM670/671NL) and mutant PS1 with the
L166P mutation. Breeding pairs were obtained
from Dr. Mathias Jucker, University of Tübin-
gen, Tübingen,Germany (Radde et al., 2006). To
replace themurineApoe genewith humanAPOE
isoforms,APPPS1-21mice were bred with either
APOE3/3 or APOE4/4 knock-in mice. APPPS1-
21/APOE3/Apoe mice and APOE3/Apoe mice
from the first generationwere bredwith each other
to generate APPPS1-21/APOE3/3 and APOE3/3
mice. APPPS1-21/APOE3/3 and APOE3/3 mice
were then bred to generate more APPPS1-21/
APOE3/3 mice. After successful generation of
APPPS1-21/APOE3/3 mice at the third genera-
tion, APPPS1-21/APOE3/3 mice were bred
withApoe knock-outmice (Jackson Laboratory).
APPPS1-21/APOE3/ mice from the fourth
generationwere bredwithAPOE3/3mice to gen-
erate APPPS1-21/APOE3/3 and APPPS1-21/
APOE3/ mice. Littermates generated at the
fifth generation were used in our analyses. Simi-
larly, APPPS1-21/APOE4/4 and APPPS1-21/
APOE4/miceweregeneratedbyusing the same
mating strategy. All mice used in this study were
maintained on a C57BL/6J background.
Quantitative real-time PCR.mRNAs were ex-
tracted from frozen cortical tissue using Trizol
and reverse transcribed with High Capacity
cDNA Reverse Transcription kit (Applied Bio-
systems). Quantitative real-time PCR (qPCR)
was performed in ABI 7500 using the default ther-
mal cycling condition with Power SYBR (Applied
Biosystems) with the following primers: forward
primer, TTGCTGGTCACATTCCTGG; and re-
verse primer, AGGTAATCCCAAAAGCGACC.
MouseGAPDH endogenous control was used as a
normalization reference. Relative mRNA levels
werecalculatedbycomparativeCtmethod.Tocon-
firm the specificity of qPCR reactions, dissociation
curveswere analyzed at the endof the qPCRassay.
Western blots. Cortical tissues were gently
lysed in PBS and modified RIPA (1% NP-40, 1% sodium deoxycholate,
25 mM Tris-HCl, 150 mMNaCl) in the presence of 1 protease inhibitor
mixture (Roche). Tissue homogenates were centrifuged at 18,000 relative
centrifugal force (rcf) for 30 min. Equal amounts of protein for each
samplewere run on 4–12%Bis-Tris XT gels (Bio-Rad) and transferred to
PVDF membranes. Blots were probed with the following antibodies:
apoE (Academy Biomedical); APP (ZYMED); PS1-NTF (EMD Chemi-
cals);-secretase 1 (BACE1) (Cell Signaling Technology); synaptophysin
(or SYP) (Sigma); glutamate receptor (GluR) 2/3/4 (Cell Signaling Tech-
nology); NMDAR2b (Cell Signaling Technology); postsynaptic density
protein 95 (PSD-95) (Millipore); and tubulin (Sigma). Tubulin-
normalized band intensity was quantified using NIH ImageJ software.
Sandwich ELISA for A and apoE. Cortical tissues were sequentially ho-
mogenized with PBS,modified RIPA, and 5 M guanidineHCl buffer. Tissue
homogenateswere centrifuged at 18,000 rcf for 30min after each extraction.
The levels of A and apoE were measured by enzyme-linked immunosor-
bent assay (ELISA). For A ELISA, HJ2 (anti-A35–40) and HJ7.4 (anti-
A37–42) were used as capture antibodies, and HJ5.1-biotin (anti-A13–
28) as the detection antibody. The anti-apoE monoclonal antibody WUE4
and another anti-apoE antibody (Calbiochem) were used for apoE ELISA.
Histology. Histology, staining, immunohistochemistry, and quantitative
analysiswereperformedasdescribedexcept thatweusedbiotinylatedmouse
monoclonal antibody HJ3.4 (1:1000, targeted against amino acids 1–13 of
the human A sequence) to detect A in tissue sections (Kim et al., 2009b).
Statistical analysis. To determine the statistical significance (*p 
0.05, **p  0.01, ***p  0.001), we first tested whether our datasets
passed the equal variance test (LeveneMedian test) and normality test
Figure 1. Reduction of apoE levels in human APOE haploinsufficient mice. Cortex from APOE homozygous (APOE3/3 and
APOE4/4 ) and hemizygous (APOE3/ and APOE4/) mice were used to measure apoE mRNA and protein levels. A, ApoE
mRNA levels were measured by quantitative real-time PCR. B, Levels of PBS-soluble apoE were assessed by probing a
membrane with anti-apoE antibody. C, Quantitative analyses of Western blots were performed with tubulin normalization
(n 4 per genotype). D, E, To validate the Western blot data, apoE levels were also measured by using an apoE-specific
ELISA from APOE3/3 and APOE3/ mice (D) and APOE4/4 and APOE4/ mice (E) (n 9 –18 per genotype). F, Levels of
APP, APP CTFs, PS1 NTF, and BACE1 proteins were measured by Western blotting (n 4 per genotype). Levels of these
proteins after normalizing with tubulin signals were not significantly altered by APOE haploinsufficiency. All graphs
represent values in mean SEM.
Figure 2. Decreased A accumulation in human APOE haploinsufficient mice. Cortical tis-
sues from 3-month-old APOE homozygous and hemizygous mice were sequentially homoge-
nizedwith PBS and RIPA. Aggregated forms of A in the RIPA-insoluble pellet were solubilized
with 5 M guanidine HCl buffer. A, B, RIPA-insoluble A40 (A) and A42 levels (B) were mea-
sured from APOE3/3 and APOE3/ mice. C, D, Similarly, RIPA-insoluble A40 (C) and A42
levels (D) were measured from APOE4/4 and APOE4/mice. (n 12–20 per genotype).
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(Kolmogorov–Smirnov test) (SigmaStat 3.5.). After confirmation that
the data did not violate the assumptions of parametric testing, a two-
tailed Student’s t test was used (GraphPad Prism 5). Variance in all
graphs represents SEM.
Results
Generation of human APOE haploinsufficient mouse models
To directly examine the effect of decreasing human apoE levels
on A and amyloid deposition, we generated mouse models that
have either one or two copies of the human APOE3 or APOE4
gene along with the APPswe/PS1(L166P) transgene (APPPS1-21
mice). APOE knock-in mouse models that express human apoE
isoforms under the control of endogenous regulatory elements
were used, eliminating any potentially confounding effects due to
the presence of the endogenous murine Apoe gene.
First, we assessed the effect of APOE gene haploinsufficiency on
apoE mRNA and protein levels in the cortex. As expected, apoE
mRNA levels decreased by50% in the hemizygousAPOE3/ and
APOE4/ mice (Fig. 1A). Western blot
analysis indicated that apoE protein levels
were also significantly decreased in the
APOE hemizygous compared with APOE
homozygous mice (Fig. 1B,C). Consistent
with the Western blot data, a similar de-
crease in apoE levels was observed by apoE
ELISA for bothAPOE3 andAPOE4 isoform
mice (Fig. 1D,E). There were no significant
alterations in the levels of proteins involved
in A production (Fig. 1F).
Haploinsufficiency of human APOE
dramatically inhibits A accumulation
To determine the effect of APOE geno-
type and dosage on A, we analyzed
A accumulation in APOE homozygous
and hemizygous mice. Significant re-
ductions in insoluble A40 and A42
levels were observed in APOE3/ mice,
compared with APOE3/3mice (Fig. 2A,B).
APOE4/ mice also had a dramatic de-
crease in insoluble A40 and A42 levels
compared with APOE4/E4 mice (Fig.
2C,D). We also analyzed PBS-soluble A
levels in mice of all genotypes. Soluble A
levels were 100-fold less than PBS-
insoluble A levels. PBS soluble A levels,
except A42 levels between APOE4/4 and
APOE4/mice, were not altered by APOE
haploinsufficiency (APOE3/3: A40, 5.82
0.31 pg/mg; A42, 0.77  0.068 pg/mg;
APOE3/: A40, 5.270.32pg/mg;A42,
0.77  0.099 pg/mg; APOE4/4: A40,
7.49  0.88 pg/mg; A42, 1.39  0.13 pg/
mg; APOE4/: A40, 7.90  0.51 pg/mg;
A42, 1.12 0.058 pg/mg).
Reduction of A and fibrillar A
plaque load in human APOE
hemizygous mice
Todetermine the extent ofAdeposition in
APOE homozygous and hemizygous mice,
brain sections from3-month-oldmicewere
immunostainedwith abiotinylated anti-A
antibody, HJ3.4 (Fig. 3A–F). Quantitative
analyses of anti-A immunostaining demonstrated that A plaque
load was significantly decreased in APOE3/mice compared with
APOE3/3 mice (Fig. 3C). The level of A deposition in both
APOE4/4 and APOE4/mice was also analyzed in the same way
(Fig. 3D,E). While APOE4/ and APOE4/ mice had signifi-
cantly greater A deposition than APOE3/ and APOE3/
mice respectively, APOE4/ mice had a dramatic reduction in
A plaque load, compared with APOE4/4 mice (Fig. 3F). To
further characterize the nature of the depositedA plaques, brain
sections were stained with X-34 dye that selectively detects only
fibrillar, but not diffuse, A deposits. Consistent with the
anti-A antibody staining, APOE3/ and APOE4/ hemizy-
gous mice had significantly less X-34-positive fibrillar plaque
load, compared with APOE3/3 and APOE4/4 homozygous
mice (Fig. 3G–L). Together, our results clearly demonstrate
that haploinsufficiency of APOE decreases both total A and
fibrillar amyloid deposition.
Figure 3. Haploinsufficiency of human APOE leads to reduction of A and fibrillar A plaque deposition. A, B, D, E, Brain
sections from 3-month-old APOE homozygous (A, D) and hemizygous (B, E) mice were immunostained for amyloid with anti-A
antibody (HJ3.4-biotin). Scale bars, 400m. A–C, The extent of A deposition detected by HJ3.4-biotin antibodywas quantified
(C) from cortex of APOE3/3 (A) and APOE3/mice (B).D–F, The extent of A deposition detectedwas quantified (F ) from cortex
of APOE4/4 (D) and APOE4/mice (E). G,H, J, K, Brain sections from 3-month-old APOE homozygous (G, J ) and hemizygous (H,
K )micewere stainedwith X-34dye that recognizes only fibrillar plaques. Scale bar, 200m.G–I, Fibrillar plaque loaddetected by
X-34 dye was quantified (I ) from cortex of APOE3/3 homozygous (G) and APOE3/mice (H ). J–L, The extent of fibrillar plaque
load was also analyzed (L) from cortex of APOE4/4 (J ) and APOE4/mice (E). (n 12–20 per genotype).
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APOE dosage-dependent modulation of
neuroinflammatory response
Aberrant inflammatory responses, such
as activation of microglia, are common
pathological features in the brains of AD
patients. To identify activated microglia
in the brain, mouse brain sections were
stained with anti-CD45 antibody, a
marker of microgliosis. Plaque-associated
microglial activation was evident around
A deposits in APPPS1-21 mice with
APOE isoforms (Fig. 4A–D). Quantitative
analysis of microgliosis indicated an95%
decrease in the CD45-positive activatedmi-
croglial load in APOE3/ mice, compared
withAPOE3/3 littermates (Fig. 4E). A simi-
lar dramatic phenotype was observed be-
tween APOE4/4 and APOE4/ mice (Fig.
4C,D). There was an 97% reduction in
microgliosis in APOE4/ mice (Fig. 4F).
These findings indicate that the reduc-
tion of A and amyloid formation by
APOE haploinsufficiency is closely asso-
ciated with an attenuation of the micro-
glial neuroinflammatory response. We
also analyzed the levels of presynaptic
and postsynaptic proteins. Analysis of
synaptophysin, GluR2/3/4, NMDA re-
ceptor 2b, and PSD-95 levels indicated
there was no significant alteration in
these proteins between genotypes or
APOE dosage levels (Fig. 4G).
Discussion
We tested whether decreasing human apoE
levels will increase or decrease A accumu-
lation in vivo. Given the importance of this
question, there have been numerous at-
tempts to investigate the effects of modu-
lating apoE levels onADpathogenesis (Ash-
ford, 2002; Rebeck et al., 2002; Teter et al.,
2002). However, studies ranging from in
vitroA aggregation, ex vivoA assays, and
pharmacological approaches have provided
conflicting results (Kim et al., 2009a). Most
in vivo studies also provided limited infor-
mation regarding the effect of human apoE
modulation, since they indirectly inferred
the effect of human apoE based on the ma-
nipulation of mouse apoE. To overcome
some of the limitations of previous studies,
we took a genetic approach by generating hu-
manAPOEhomozygousorhemizygousmice
without the presence of the confounding en-
dogenous mouse Apoe gene. A-depositing
mouse models with two copies (APOE3/3 or
APOE4/4) or one copy (APOE3/ or
APOE4/) of each APOE isoform were suc-
cessfully generated.APOE3/ andAPOE4/
mice had significantly less A accumulation, amyloid deposition,
and microgliosis compared with the respective homozygous litter-
mates. Thus, decreasing human apoE levels may be an attractive
therapeutic strategy for attenuating A deposition and its down-
stream effects in AD.
Given the critical role of A in AD pathogenesis, the effect of
apoE isoforms on A deposition has been extensively investi-
Figure 4. Attenuation of microgliosis in human APOE haploinsufficient mice. A–D, Brain sections from 3-month-old
male APOE homozygous (A, C) and male hemizygous (B, D) mice were immunostained with an antibody against
activated microglial CD45. E, The percentage area covered by CD45 staining was quantified from the cortex of APOE3/3 and
APOE3/ mice. F, The extent of microgliosis was also quantified from the cortex of APOE4/4 and APOE4/ mice. Scale
bars: lower magnification, 200 m; higher magnification, 90 m. n  6 –12 male mice per genotype. G, Levels of
synaptophysin, GluR2/3/4, NMDA receptor 2b, and PSD-95 levels were measured by Western blotting (n 4 per geno-
type). Levels of these proteins after normalizing with tubulin signals were not significantly altered by APOE genotype or
haploinsufficiency.
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gated. APOE isoform-dependent amyloid deposition has been
consistently observed in humans and A-depositing mouse
models (Holtzman et al., 2000; Bales et al., 2009; Reiman et al.,
2009; Morris et al., 2010). Consistent with previous studies with
other APP mouse models, we also observed APOE isoform-
dependent effects on A deposition in the APPPS1-21 mouse
model (E4 E3). Since apoE levels differ between APOE4/4 and
APOE3/3, with levels of apoE4 being lower than apoE3, it is
tempting to speculate that the difference in A accumulation
between the apoE isoforms is due to differences in apoE3 versus
apoE4 levels. However, the structures of apoE3 and apoE4 differ
significantly from each other (Mahley et al., 2006), and the ob-
served difference in A deposition cannot be simply attributed to
apoE4 levels being lower than apoE3. For example, APOE4/E4
mice have greater amyloid deposition than APOE3/ mice de-
spite the fact that apoE4 levels are higher in theAPOE4/E4 than in
the APOE3/ mice. APOE gene dosage-dependent amyloid de-
position could be due to an effect of an alteration in A clearance
and/or aggregation. Several studies demonstrated that apoE iso-
forms can differentially affect A clearance (Deane et al., 2008;
Jiang et al., 2008; Castellano et al., 2011). ApoE isoforms may be
slowing A clearance in an apoE-isoform-dependent manner
(E4  E3  E2). This idea is supported by the fact that mice
lacking apoE have accelerated A clearance from the brain rela-
tive to apoE-expressing mice (DeMattos et al., 2004). Another
potentially important mechanism is direct facilitation of A fi-
brillogenesis by an ApoE and A interaction. While there are a
few conflicting reports (Kim et al., 2009a), several groups have
reported that all three apoE isoforms increase A fibrillogenesis,
with the effect being most exacerbated with ApoE4 and the least
with ApoE2 (Ma et al., 1994; Wisniewski et al., 1994; Castano et
al., 1995).
Given the isoform-dependent effect on AD pathology, one
therapeutic approach is to convert apoE4 to an apoE3-like pro-
tein by using a small molecule (Mahley et al., 2006). Disrupting
the apoE–A interaction could be another attractive therapeutic
approach to prevent apoE-mediated A aggregation (Sadowski
et al., 2004). Previous studies suggested that modulation of apoE
levels and lipidation state, independent of APOE genotype, may
be another potential strategy to decrease A accumulation (Cao
et al., 2006; Wahrle et al., 2008; Kim et al., 2009b). Interestingly,
deletion of ATP-binding cassette, subfamily A1 (Abca1) and liver
x receptor (Lxr) genes decreased apoE levels but increased or had
no effect on A deposition (Hirsch-Reinshagen et al., 2005; Kol-
damova et al., 2005; Wahrle et al., 2005; Zelcer et al., 2007). In
addition, several studies have shown that activation of Lxr in-
creases mouse apoE and decreases A levels (Jiang et al., 2008).
However, it is difficult to interpret the effect of altering apoE level
in these studies, since modulation of Abca1 and Lxr also influ-
ences the lipidation state of apoE. Whether reducing human
apoE levels without affecting its lipidation state will promote or
attenuate A accumulation was not clear from previous studies.
Our study demonstrates the beneficial effect of decreasing apoE
levels on A accumulation. Consistent with our finding, low lev-
els of apoE were strongly associated with low cerebral A load in
humans (Darreh-Shori et al., 2011).APOE gene promoter studies
also suggest that higher levels of apoE, regardless of isoform sta-
tus, increase the risk of developing AD (Laws et al., 2003). APOE
may also influence risk for ADbymechanisms that are not related
to A. We found no clear differences in presynaptic and postsyn-
aptic proteins in APPPS1-21 mice of different APOE genotypes
and doses. This, however, does not rule out the possibility the
structural synaptic changes might be present that have been ob-
served by others (Dumanis et al., 2009). Our results in which
apoE levels are altered by changing gene dosage suggest that strat-
egies to decrease apoE levels in the brain should be further ex-
plored for the prevention/treatment of AD. Changing apoE levels
in an adult in the context of two copies of APOE is different than
having a lifelong genetic alteration of APOE dosage as in our
experiments. It will be important to see in the former context
whether altering apoE levels in an adult with two endogenous
copies ofAPOEhas similar or different effects aswe report herein.
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